Your cart is empty
Browse transcripts and add items to get started.
Analyzes the biotech clinical trials ecosystem, highlighting CRO performance metrics, oncology-driven demand, Phase II–III bottlenecks, and shift toward unified digital platforms improving efficiency and data management.
This transcript examines the biotech clinical trials ecosystem, where growth is driven by increased investment post-COVID, particularly in oncology, gene therapy, and immunology. CROs play a critical role, with revenue increasingly coming from small and mid-sized biotech firms outsourcing trials.
Key performance metrics include enrollment rates, site activation timelines, and data lock speeds. The industry is shifting toward unified digital platforms led by Medidata and Veeva.
Major challenges include Phase II–III transition bottlenecks, cost overruns, and patient recruitment inefficiencies.
